<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Biol Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Biol Chem</journal-id><journal-id journal-id-type="pmc-domain-id">567</journal-id><journal-id journal-id-type="pmc-domain">jbc</journal-id><journal-title-group><journal-title>The Journal of Biological Chemistry</journal-title></journal-title-group><issn pub-type="ppub">0021-9258</issn><issn pub-type="epub">1083-351X</issn><publisher><publisher-name>American Society for Biochemistry and Molecular Biology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11154709</article-id><article-id pub-id-type="pmcid-ver">PMC11154709.1</article-id><article-id pub-id-type="pmcaid">11154709</article-id><article-id pub-id-type="pmcaiid">11154709</article-id><article-id pub-id-type="pmid">38703998</article-id><article-id pub-id-type="doi">10.1016/j.jbc.2024.107332</article-id><article-id pub-id-type="pii">S0021-9258(24)01833-7</article-id><article-id pub-id-type="publisher-id">107332</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>JBC Communication</subject></subj-group></article-categories><title-group><article-title>4S-fluorination of ProB29 in insulin lispro slows fibril formation</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Breunig</surname><given-names initials="SL">Stephanie L.</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Chapman</surname><given-names initials="AM">Alex M.</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>LeBon</surname><given-names initials="J">Jeanne</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Quijano</surname><given-names initials="JC">Janine C.</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Ranasinghe</surname><given-names initials="M">Maduni</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Rawson</surname><given-names initials="J">Jeffrey</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Demeler</surname><given-names initials="B">Borries</given-names></name><xref rid="aff3" ref-type="aff">3</xref><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>Ku</surname><given-names initials="HT">Hsun Teresa</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author" id="au9"><name name-style="western"><surname>Tirrell</surname><given-names initials="DA">David A.</given-names></name><email>tirrell@caltech.edu</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp">&#8727;</xref></contrib><aff id="aff1"><label>1</label>Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California, USA</aff><aff id="aff2"><label>2</label>Department of Translational Research and Cellular Therapeutics, Arthur Riggs Diabetes and Metabolism Research Institute, Beckman Research Institute City of Hope, Duarte, California, USA</aff><aff id="aff3"><label>3</label>Department of Chemistry and Biochemistry, University of Lethbridge, Lethbridge, Alberta, Canada</aff><aff id="aff4"><label>4</label>Department of Chemistry and Biochemistry, University of Montana, Missoula, Montana, USA</aff><aff id="aff5"><label>5</label>Irell &amp; Manella Graduate School of Biological Science, City of Hope, Duarte, California, USA</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8727;</label>For correspondence: David A. Tirrell <email>tirrell@caltech.edu</email></corresp></author-notes><pub-date pub-type="collection"><month>6</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>03</day><month>5</month><year>2024</year></pub-date><volume>300</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">462895</issue-id><elocation-id>107332</elocation-id><history><date date-type="received"><day>21</day><month>11</month><year>2023</year></date><date date-type="rev-recd"><day>2</day><month>4</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>05</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>06</day><month>06</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-07 11:25:31.400"><day>07</day><month>06</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 The Authors</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><p>Recombinant insulin is a life-saving therapeutic for millions of patients affected by diabetes mellitus. Standard mutagenesis has led to insulin variants with improved control of blood glucose; for instance, the fast-acting insulin lispro contains two point mutations that suppress dimer formation and expedite absorption. However, insulins undergo irreversible denaturation, a process accelerated for the insulin monomer. Here we replace ProB29 of insulin lispro with 4<italic toggle="yes">R</italic>-fluoroproline, 4<italic toggle="yes">S</italic>-fluoroproline, and 4,4-difluoroproline. All three fluorinated lispro variants reduce blood glucose in diabetic mice, exhibit similar secondary structure as measured by CD, and rapidly dissociate from the zinc- and resorcinol-bound hexamer upon dilution. Notably, however, we find that 4<italic toggle="yes">S</italic>-fluorination of ProB29 delays the formation of undesired insulin fibrils that can accumulate at the injection site <italic toggle="yes">in&#160;vivo</italic> and can complicate insulin production and storage. These results demonstrate how subtle molecular changes achieved through non-canonical amino acid mutagenesis can improve the stability of protein therapeutics.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>non-canonical amino acid</kwd><kwd>fluoroproline</kwd><kwd>proline</kwd><kwd>insulin</kwd><kwd>insulin lispro</kwd><kwd>fibrillation</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta><def-list><title>Abbreviations</title><def-item><term id="kwrd0045">44-diF</term><def><p>4,4-difluoroproline</p></def></def-item><def-item><term id="kwrd0055">4R-F</term><def><p>4R-fluoroproline</p></def></def-item><def-item><term id="kwrd0065">4S-F</term><def><p>4S-fluoroproline</p></def></def-item><def-item><term id="kwrd0075">ANS</term><def><p>8-anilino-1-naphthalenesulfonic acid</p></def></def-item><def-item><term id="kwrd0085">FAI</term><def><p>fast-acting insulin</p></def></def-item><def-item><term id="kwrd0095">ncPro</term><def><p>non-canonical proline</p></def></def-item></def-list><notes><p id="misc0010">Reviewed by members of the JBC Editorial Board. Edited by Karen Fleming</p></notes></front><body><p id="p0010">Insulin, a 5.8&#160;kDa peptide hormone composed of two disulfide-linked chains (A and B), is a widely-used, essential therapeutic for individuals with diabetes mellitus. Insulin is normally secreted from pancreatic &#946;-cells in response to elevated blood glucose (<xref rid="bib1" ref-type="bibr">1</xref>). Diabetes, which affects more than 400 million adults world-wide (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/publications/i/item/9789241565257" id="intref0010">https://www.who.int/publications/i/item/9789241565257</ext-link>), arises from dysfunction in insulin signaling, either from loss of insulin secretion (type 1) or from development of insulin resistance (type 2). Advances in insulin technology over the last century, notably the recombinant production of insulin (<xref rid="bib2" ref-type="bibr">2</xref>), have dramatically reduced the mortality rate associated with diabetes. Individuals with type 1 diabetes typically rely on insulin replacement therapy to compensate for loss of pancreatic function, while those with type 2 often supplement lifestyle changes with oral medications that enhance insulin signaling and, in severe cases, receive exogenous insulin.</p><p id="p0015">In its pharmaceutical formulations, insulin exists as a zinc- and phenolic ligand-bound hexamer (referred to as the R<sub>6</sub> state) (<xref rid="bib3" ref-type="bibr">3</xref>). Upon subcutaneous injection, insulin hexamers dissociate through lower-order oligomeric species before crossing the capillary membrane in the active monomeric state (<xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref>) (<xref rid="fig1" ref-type="fig">Fig.&#160;1</xref><italic toggle="yes">A</italic>). Because dissociation to the monomer is rate-limiting for insulin absorption into the bloodstream, disrupting association also accelerates onset of action (<xref rid="bib6" ref-type="bibr">6</xref>). Introducing point mutations that disfavor oligomer formation has resulted in FDA-approved fast-acting insulins (FAIs) (<xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref>). FAIs are rapidly released into the bloodstream (<xref rid="bib10" ref-type="bibr">10</xref>), approaching the transient increases in insulin concentration stimulated by elevated blood glucose. Typical insulin replacement therapies combine regular treatments of basal (long-acting) insulin variants with injections of FAIs before mealtime to approximate the insulin-action profile of a healthy pancreas (<xref rid="bib10" ref-type="bibr">10</xref>). However, insulins are prone to chemical and physical denaturation, such as the irreversible formation of amyloid fibrils. Insulin fibrils can accumulate <italic toggle="yes">in&#160;vivo</italic> at sites of repeated injection and complicate industrial production, distribution, and storage (<xref rid="bib11" ref-type="bibr">11</xref>). FAIs are more prone than human insulin to chemical and physical denaturation, since the protective effects of oligomerization are interrupted (<xref rid="bib12" ref-type="bibr">12</xref>).<fig id="fig1" position="float" orientation="portrait"><label>Figure&#160;1</label><caption><p><bold>Proline mutagenesis at position B29 of insulin lispro.</bold><italic toggle="yes">A</italic>, simplified representation of insulin and insulin lispro oligomerization. Disrupted oligomerization speeds the release of lispro into the bloodstream. <italic toggle="yes">B</italic>, the amino acid sequences of human insulin and insulin lispro. <italic toggle="yes">C</italic>, the structures of proline and the proline analogs used in this study. <italic toggle="yes">D</italic>&#8211;<italic toggle="yes">G</italic>, characterization of proline analog incorporation. Proinsulin was expressed in media supplemented with proline (<italic toggle="yes">D</italic>), 4<italic toggle="yes">R</italic>-F (<italic toggle="yes">E</italic>), 4<italic toggle="yes">S</italic>-F (<italic toggle="yes">F</italic>), 44-diF (<italic toggle="yes">G</italic>), digested with Glu-C, and analyzed by MALDI-TOF MS. The peptide-containing position B29 of mature lispro is <sup>50</sup>RGFFYTK<bold><underline>P</underline></bold>TRRE (expected m/z&#160;= 1557.8). <italic toggle="yes">H</italic>&#8211;<italic toggle="yes">K</italic>, MALDI-TOF characterization of mature insulin variants: insulin lispro (<italic toggle="yes">H</italic>), KP-4<italic toggle="yes">R</italic>-F (<italic toggle="yes">I</italic>), KP-4<italic toggle="yes">S</italic>-F (<italic toggle="yes">J</italic>), and KP-44-diF (<italic toggle="yes">K</italic>). The peaks at m/z &#8764;6050 correspond to adducts of the sinapic acid matrix. 44-diF, 4,4-difluoroproline; 4R-F, 4R-fluoroproline; 4S-F, 4S-fluoroproline.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p><p id="p0020">Insulin lispro (Humalog, Eli Lilly), the first commercially available FAI, is characterized by reduced monomer association as a consequence of the inversion of residues ProB28 and LysB29 (<xref rid="fig1" ref-type="fig">Fig.&#160;1</xref><italic toggle="yes">B</italic>) (<xref rid="bib7" ref-type="bibr">7</xref>). Removal of the constrained pyrrolidine ring of proline at position B28 grants additional conformational degrees of freedom and removes hydrophobic packing interactions at the dimer interface. These modifications disrupt the homodimer interaction (<xref rid="bib7" ref-type="bibr">7</xref>) and accelerate absorption (<xref rid="bib6" ref-type="bibr">6</xref>). However, the standard mutagenesis approach employed in the discovery of insulin lispro (<xref rid="bib7" ref-type="bibr">7</xref>) (and other FDA-approved insulin variants (<xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref>, <xref rid="bib13" ref-type="bibr">13</xref>)) is limited by the chemical functionality available in the 20 canonical amino acids and restricted with respect to the chemical space that can be explored. In particular, no other canonical amino acid can recapitulate the unique structural and conformational properties of proline (<xref rid="bib14" ref-type="bibr">14</xref>). In contrast, protein engineering strategies that draw upon non-canonical amino acids afford access to chemistries beyond those found in natural or conventionally-engineered proteins (<xref rid="bib15" ref-type="bibr">15</xref>).</p><p id="p0025">Non-canonical proline (ncPro) residues provide chemical diversity while maintaining proline&#8217;s cyclic structure. Many ncPro residues exhibit conformational biases different from those of proline (<xref rid="bib14" ref-type="bibr">14</xref>) and have been used to interrogate the importance of proline conformation in protein behavior. Proline analogs with 4<italic toggle="yes">R</italic> electron-withdrawing groups (such as 4<italic toggle="yes">R</italic>-fluoroproline, 4<italic toggle="yes">R</italic>-F; <xref rid="fig1" ref-type="fig">Fig.&#160;1</xref><italic toggle="yes">C</italic>) promote a C<sup>&#947;</sup>-<italic toggle="yes">exo</italic> ring pucker due to a gauche effect, which in turn enforces the <italic toggle="yes">trans</italic> amide isomer. Conversely, ncPro residues with 4<italic toggle="yes">S</italic>-electron&#8211;withdrawing groups (such as 4<italic toggle="yes">S</italic>-fluoroproline, 4<italic toggle="yes">S</italic>-F) favor the C<sup>&#947;</sup>-<italic toggle="yes">endo</italic> pucker and the <italic toggle="yes">cis</italic> amide isomer, compared to canonical proline (<xref rid="bib14" ref-type="bibr">14</xref>). The position of the amide <italic toggle="yes">cis</italic>-<italic toggle="yes">trans</italic> equilibrium of 4,4-difluoroproline (44-diF) is similar to that of proline (<xref rid="bib16" ref-type="bibr">16</xref>). Isomerization of the fluorinated analogs is accelerated relative to proline, as an inductive effect reduces the bond order of the preceding amide (<xref rid="bib16" ref-type="bibr">16</xref>). Proline analogs have been used to determine the stereoelectronic origin of collagen stability (<xref rid="bib17" ref-type="bibr">17</xref>), to identify a key <italic toggle="yes">cis</italic>-<italic toggle="yes">trans</italic> isomerization event in the opening of the 5-HT<sub>3</sub> receptor (<xref rid="bib18" ref-type="bibr">18</xref>), to probe the role of <italic toggle="yes">cis-trans</italic> isomerization in &#946;2 microglobulin fibrillation (<xref rid="bib19" ref-type="bibr">19</xref>), and to modify protein stability (<xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref>).</p><p id="p0030">We recently demonstrated that introduction of ncPro residues at position B28 can be used to tune the biophysical properties of human insulin (<xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref>, <xref rid="bib25" ref-type="bibr">25</xref>). These results prompted us to ask whether similar changes in the biophysical properties of insulin lispro might be achieved. To explore this question, we replaced ProB29 in insulin lispro with 4-fluorinated proline analogs (<xref rid="fig1" ref-type="fig">Fig.&#160;1</xref><italic toggle="yes">C</italic>); these lispro variants will be referred to as KP-4<italic toggle="yes">R</italic>-F, KP-4<italic toggle="yes">S</italic>-F, and KP-44-diF (KP refers to the inversion of the positions of the lysine (K) and proline (P) residues in the lispro sequence).</p><sec id="sec1"><title>Results</title><p id="p0035">Lispro variants were expressed in <italic toggle="yes">Escherichia coli</italic> as the corresponding proinsulins (precursors to insulin) under conditions that favor ncPro incorporation (<xref rid="bib26" ref-type="bibr">26</xref>) at position B29. Briefly, the proline auxotrophic strain <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="CAG18515">CAG18515</ext-link>, engineered to overexpress the <italic toggle="yes">E.&#160;coli</italic> prolyl-tRNA synthetase, was grown in M9 medium supplemented with all 20 amino acids until late log phase. Cells were washed and resuspended in a medium lacking proline, at which point 0.3 to 0.5&#160;M NaCl (to facilitate proline uptake) and the proline analog (0.5&#160;mM) were added. The extent of proline replacement was assessed by MALDI-TOF mass spectrometry of a proinsulin peptide fragment (<xref rid="fig1" ref-type="fig">Fig.&#160;1</xref>, <italic toggle="yes">D</italic>&#8211;<italic toggle="yes">G</italic>) and of mature insulin (<xref rid="fig1" ref-type="fig">Fig.&#160;1</xref>, <italic toggle="yes">H</italic>&#8211;<italic toggle="yes">K</italic>). Incorporation of all of the fluorinated proline analogs exceeded 90% (<xref rid="appsec1" ref-type="sec">Table&#160;S1</xref>). The yield of proinsulin-lispro in rich medium was 33&#160;mg&#160;L<sup>&#8722;1</sup>; 4<italic toggle="yes">R</italic>-F incorporation led to a nearly identical proinsulin yield, while incorporation of the other two analogs led to a significant decrease in proinsulin expression (7&#8211;8&#160;mg&#160;L<sup>&#8722;1</sup>; <xref rid="appsec1" ref-type="sec">Table&#160;S2</xref>). Proinsulins were refolded, digested with trypsin and carboxypeptidase B, and purified to achieve mature lispro variants (<xref rid="appsec1" ref-type="sec">Table&#160;S2</xref>, and <xref rid="appsec1" ref-type="sec">Fig.&#160;S1</xref>).</p><p id="p0040">To verify bioactivity, lispro variants were injected subcutaneously into diabetic mice, and blood glucose was monitored over 2.5&#160;h. Mouse models allow determination of activity but not time to onset of action (<xref rid="bib27" ref-type="bibr">27</xref>). Because the C-terminus of the B-chain does not participate in binding to the insulin receptor (<xref rid="bib28" ref-type="bibr">28</xref>), we did not expect substitution at position B29 to affect bioactivity. As expected, all lispro variants retained activity (<xref rid="fig2" ref-type="fig">Fig.&#160;2</xref><italic toggle="yes">A</italic>). Further, lower lispro doses&#8212;5 to 10% of the standard injection, representing the residual proline-containing lispro present in our lispro analog preparations (<xref rid="appsec1" ref-type="sec">Table&#160;S1</xref>)&#8212;did not similarly reduce blood glucose in diabetic mice (<xref rid="appsec1" ref-type="sec">Fig.&#160;S2</xref>). These results demonstrate that our fluorinated variants are active <italic toggle="yes">in&#160;vivo</italic>.<fig id="fig2" position="float" orientation="portrait"><label>Figure&#160;2</label><caption><p><bold>Biological activity and CD spectroscopy of lispro variants.</bold><italic toggle="yes">A</italic>, lispros were injected subcutaneously into diabetic mice, and blood glucose was measured over time after injection. The data presented here represent the mean&#160;&#177; SD of 3 to 6 biological replicates. <italic toggle="yes">B</italic>&#8211;<italic toggle="yes">E</italic>, far-UV circular dichroism spectra (60&#160;&#956;M lispro in 10&#160;mM phosphate buffer, pH 8.0). The spectrum of lispro is overlaid with that of human insulin (<italic toggle="yes">B</italic>), KP-4<italic toggle="yes">R</italic>-F (<italic toggle="yes">C</italic>), KP-4<italic toggle="yes">S</italic>-F (<italic toggle="yes">D</italic>), and KP-44diF (<italic toggle="yes">E</italic>). 4R-F, 4R-fluoroproline; 4S-F, 4S-fluoroproline.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="p0045">The secondary structure of each insulin lispro variant was probed by circular dichroism spectroscopy. Compared to human insulin, which exists as a dimer at 60&#160;&#956;M, the monomeric insulin lispro exhibits increased negative ellipticity at 208&#160;nm and decreased negative ellipticity at 222&#160;nm (<xref rid="fig2" ref-type="fig">Fig.&#160;2</xref><italic toggle="yes">B</italic>), consistent with previous measurements (<xref rid="bib7" ref-type="bibr">7</xref>). The CD spectra of all of the fluorinated lispro variants were similar to that of lispro (<xref rid="fig2" ref-type="fig">Fig.&#160;2</xref>, <italic toggle="yes">C</italic>&#8211;<italic toggle="yes">E</italic>), suggesting that fluorination does not alter the secondary structure of the protein. All lispro samples were further analyzed by analytical ultracentrifugation (<xref rid="appsec1" ref-type="sec">Fig.&#160;S3</xref>). To determine the dissociation constant of each variant, we fit the data to a reversible monomer-dimer equilibrium (<xref rid="bib29" ref-type="bibr">29</xref>). The K<sub>d</sub> obtained for lispro, 0.65&#160;mM, 95% confidence interval [0.27&#8211;1.02], is in reasonable agreement with the value of 1.1&#160;mM previously reported (<xref rid="bib7" ref-type="bibr">7</xref>). Similar K<sub>d</sub> values for each fluorinated lispro variant (1.32&#8211;1.88&#160;mM, <xref rid="appsec1" ref-type="sec">Table&#160;S3</xref>) confirmed the preference for the monomer state across all samples (<xref rid="appsec1" ref-type="sec">Fig.&#160;S3</xref>, and <xref rid="appsec1" ref-type="sec">Table&#160;S3</xref>).</p><p id="p0050">We measured the half-life (t<sub>1/2</sub>) for dissociation of the hexamer form of each lispro variant by monitoring the change in negative ellipticity at 222&#160;nm over time after dilution (<xref rid="fig3" ref-type="fig">Figs.&#160;3</xref><italic toggle="yes">A</italic>, <xref rid="appsec1" ref-type="sec">S4</xref>, and <xref rid="appsec1" ref-type="sec">S5</xref>). Insulin and lispro variants were formulated to mimic the pharmaceutical formulation (600&#160;&#956;M insulin, 25&#160;mM resorcinol, 250&#160;&#956;M ZnCl<sub>2</sub>); resorcinol was used as the phenolic ligand to slow dissociation (<xref rid="bib30" ref-type="bibr">30</xref>). Under these conditions, insulin lispro dissociated significantly more rapidly than human insulin (t<sub>1/2</sub>&#160;= 11.3&#160;&#177; 3.8 and 30.2&#160;&#177; 2.8&#160;s, respectively), as expected. Monitoring dissociation processes faster than that of lispro is limited by the mixing time of this experiment, though comparisons to human insulin can still be made. All of the fluorinated lispro variants dissociated faster than human insulin under the conditions used here (<xref rid="fig3" ref-type="fig">Fig.&#160;3</xref>, <italic toggle="yes">B</italic>&#8211;<italic toggle="yes">G</italic>, and <xref rid="appsec1" ref-type="sec">Table&#160;S4</xref>).<fig id="fig3" position="float" orientation="portrait"><label>Figure&#160;3</label><caption><p><bold>Hexamer dissociation kinetics of lispro variants.</bold><italic toggle="yes">A</italic>, equilibrium CD spectra of lispro before and after dilution. To measure dissociation kinetics, the decrease in negative ellipticity at 222&#160;nm was monitored over time after dilution. <italic toggle="yes">B</italic>&#8211;<italic toggle="yes">F</italic>, representative dissociation kinetics measurements for human insulin (<italic toggle="yes">B</italic>), lispro (<italic toggle="yes">C</italic>), KP-4<italic toggle="yes">R</italic>-F (<italic toggle="yes">D</italic>), KP-4<italic toggle="yes">S</italic>-F (<italic toggle="yes">E</italic>), KP-44diF (<italic toggle="yes">F</italic>). Note the extended x-axis for insulin in panel <italic toggle="yes">B</italic>.&#160;G, summary of dissociation half-life values; replicate measurements for each sample originate from at least two separate HPLC fractions, measured on different days. 4R-F, 4R-fluoroproline; 4S-F, 4S-fluoroproline.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p><p id="p0055">Each insulin lispro variant was subjected to continuous, vigorous shaking at 37 &#176;C to assess its stability against physical denaturation; fibrillation was monitored with the dye thioflavin T, (<xref rid="fig4" ref-type="fig">Fig.&#160;4</xref><italic toggle="yes">A</italic>). Under these conditions, the fibrillation lag time of insulin lispro (10.9&#160;&#177; 2.2&#160;h) was reduced compared to that of human insulin (16.7&#160;&#177; 4.1&#160;h) (<xref rid="bib25" ref-type="bibr">25</xref>), consistent with the conventional view that fibrillation proceeds from the monomer state (<xref rid="bib11" ref-type="bibr">11</xref>). Replacing ProB29 with 4<italic toggle="yes">R</italic>-F (10.3&#160;&#177; 2.4&#160;h) or 44-diF (9.0&#160;&#177; 1.3&#160;h) did not significantly change the fibrillation lag time. Notably, KP-4<italic toggle="yes">S</italic>-F was stabilized against fibril formation (17.9&#160;&#177; 0.8&#160;h). TEM analysis of the lispro fibrils revealed similar morphology among samples (<xref rid="fig4" ref-type="fig">Fig.&#160;4</xref>, <italic toggle="yes">B</italic>&#8211;<italic toggle="yes">E</italic>).<fig id="fig4" position="float" orientation="portrait"><label>Figure&#160;4</label><caption><p><bold>Fibrillation of lispro variants.</bold><italic toggle="yes">A</italic>, lispro variants (60&#160;&#956;M in 100&#160;mM phosphate buffer, pH 8.0) were incubated at 37 &#176;C with vigorous shaking; fibril formation was monitored by ThT fluorescence. Fibrillation runs were performed on two separate HPLC fractions, each in triplicate or quadruplicate, on two separate days.&#160;<italic toggle="yes">B</italic>&#8211;<italic toggle="yes">E</italic>, TEM images of lispro (<italic toggle="yes">B</italic>), KP-4<italic toggle="yes">R</italic>-F (<italic toggle="yes">C</italic>), KP-4<italic toggle="yes">S</italic>-F (<italic toggle="yes">D</italic>), and KP-44-diF (<italic toggle="yes">E</italic>) aggregates. <italic toggle="yes">F</italic>, ANS emission spectra of lispro variants (1&#160;&#956;M lispro variant labeled with 5&#160;&#956;M ANS in 100&#160;mM phosphate buffer, pH 8.0). The data presented here indicate the mean&#160;&#177; SD for each variant from measurements of three separate HPLC fractions. 44-diF, 4,4-difluoroproline; 4R-F, 4R-fluoroproline; 4S-F, 4S-fluoroproline; ThT, thioflavin T.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p><p id="p0060">We probed the extent of conformational disorder of each lispro variant using the dye 8-anilino-1-naphthalenesulfonic acid (ANS), which exhibits a blue shift in its emission maximum upon binding to hydrophobic patches of proteins indicative of a molten globule state (<xref rid="bib31" ref-type="bibr">31</xref>). The emission spectra of all lispro variants were similar upon addition of ANS (<xref rid="fig4" ref-type="fig">Fig.&#160;4</xref><italic toggle="yes">F</italic>), suggesting that the observed differences in fibrillation propensity were not due to variations in protein disorder. We note that 4<italic toggle="yes">S</italic>-F more strongly favors the <italic toggle="yes">endo</italic> ring pucker and <italic toggle="yes">cis</italic> amide isomer than the other proline analogs examined in this study (<xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib32" ref-type="bibr">32</xref>). Perhaps these conformational preferences at the C terminus of the B-chain inhibit the formation of nuclei that precede fibril formation.</p></sec><sec id="sec2"><title>Discussion</title><p id="p0065">Non-canonical amino acid mutagenesis provides a convenient method for the synthesis of insulin lispro variants fluorinated at ProB29. While most of the properties of the fluorinated variants are similar to those of lispro, we find that 4<italic toggle="yes">S</italic>-fluorination at position ProB29 stabilizes the protein against fibril formation. Approaches to protect insulin against denaturation often rely upon promoting oligomerization (<xref rid="bib33" ref-type="bibr">33</xref>). However, here we observe stabilization of a monomeric FAI without changes in association behavior. Similar stabilization from the ligand-free, monomer state was observed for an insulin lispro variant that contains a 3-iodo substituent at TyrB26 (<xref rid="bib34" ref-type="bibr">34</xref>). Iodination slowed hexamer dissociation in <italic toggle="yes">in&#160;vitro</italic> studies, suggesting lispro&#8217;s rapid-acting behavior might be attenuated after subcutaneous injection in a human. Conversely, we were unable to detect differences in hexamer dissociation kinetics in our fluorinated lispro variants. In neither case is the mechanism of stabilization against fibril formation understood. ncPro substitution can impart long-range conformational effects (<xref rid="bib35" ref-type="bibr">35</xref>), and the molecular mechanism of insulin fibrillation is not fully established (<xref rid="bib11" ref-type="bibr">11</xref>). Perhaps the conformational preferences of 4S-F (<italic toggle="yes">endo</italic> ring pucker and <italic toggle="yes">cis</italic> amide isomer) may contribute to delayed fibril formation.</p><p id="p0070">Regardless of the mechanism, the discovery of a monomeric insulin with an extended lag time to fibril formation (KP-4<italic toggle="yes">S</italic>-F) is relevant to the design of improved insulin therapies. Current insulin formulations must be stored at 4 &#176;C and have limited shelf-lives. The inherent sensitivity of insulin to chemical and physical denaturation is especially problematic for long-term storage in continuous subcutaneous insulin infusion pumps (<xref rid="bib36" ref-type="bibr">36</xref>) and in efforts to provide insulin-replacement therapies to individuals without regular access to refrigeration (<xref rid="bib37" ref-type="bibr">37</xref>).</p><p id="p0075">The results of this work highlight the ability of non-canonical amino acid mutagenesis to modulate pharmaceutically relevant properties of therapeutic proteins. ncPro mutagenesis allows for the modification of insulin lispro at position B29 without losing the unique conformational restrictions characteristic of proline, and the fluorinated insulin lispro variants introduced here can be produced through straightforward bacterial expression. Further work is needed to elucidate the molecular origins of the stabilization of KP-4<italic toggle="yes">S</italic>-F.</p></sec><sec id="sec3"><title>Experimental procedures</title><p id="p0080">Detailed methods are provided in the <xref rid="appsec1" ref-type="sec">Supporting Information</xref>.</p><sec id="sec3.1"><title>Preparation of insulin and lispro variants</title><p id="p0085">Human insulin and lispro variants were prepared as previously described (<xref rid="bib25" ref-type="bibr">25</xref>); details are provided in the <xref rid="appsec1" ref-type="sec">Supporting information</xref>. Incorporation efficiencies for all proline analogs exceeded 90% (<xref rid="appsec1" ref-type="sec">Table&#160;S1</xref>).</p></sec><sec id="sec3.2"><title>Reduction of blood glucose in diabetic mice</title><p id="p0090">Experiments were conducted according to procedures approved by the Institutional Animal Care and Use Committee at the City of Hope. Adult (8&#8211;12&#160;week old) male NODscid mice (Jackson Laboratory; stock # 001303) were injected intraperitoneally for three consecutive days with freshly prepared streptozotocin (45&#160;mg&#160;kg<sup>&#8722;1</sup> body weight, suspended in 100&#160;mM sodium citrate buffer, pH 4.5); diabetes was confirmed by the detection of high glucose levels (200&#8211;600&#160;mg&#160;dL<sup>&#8722;1</sup>) as measured by a glucomonitor (Freestyle, Abbott Diabetes Care). Lispro analogs were diluted to 100&#160;&#956;g&#160;mL<sup>&#8722;1</sup> in formulation buffer (1.6&#160;mg&#160;mL<sup>&#8722;1</sup>
<italic toggle="yes">m</italic>-cresol, 0.65&#160;mg&#160;mL<sup>&#8722;1</sup> phenol, 3.8&#160;mg&#160;mL<sup>&#8722;1</sup> sodium phosphate pH 7.4, 16&#160;mg&#160;mL<sup>&#8722;1</sup> glycerol, 0.8&#160;&#956;g&#160;mL<sup>&#8722;1</sup> ZnCl<sub>2</sub>) and injected (35&#160;&#956;g&#160;kg<sup>&#8722;1</sup>) subcutaneously at the scruff. Blood glucose was measured from blood sampled from the lateral tail vein.</p></sec><sec id="sec3.3"><title>Kinetics of hexamer dissociation</title><p id="p0095">Samples were dialyzed overnight against 28.6&#160;mM tris buffer, pH 8.0, then formulated as 600&#160;&#956;M insulin or lispro, 250&#160;&#956;M ZnCl<sub>2</sub>, 25&#160;mM resorcinol, 25&#160;mM tris, pH 8.0. A 20&#160;&#956;l aliquot of the formulation solution was injected into a stirred buffer solution containing 2.98&#160;ml of 25&#160;mM tris, pH 8.0 (150-fold dilution) at 25 &#176;C. Ellipticity was monitored over 120&#160;s at 222&#160;nm. A typical run led to a rapid drop in CD signal as mixing occurred (&#8764;5&#160;s), then a gradual rise to an ellipticity representative of an insulin monomer. Data preceding the timepoint with the greatest negative ellipticity represented the mixing time and were omitted from further analysis. Runs were discarded if the maximum change in mean residue ellipticity from equilibrium did not exceed 750 deg cm<sup>2</sup>&#160;dmol<sup>&#8722;1</sup>, which indicated poor mixing. Dissociation data were fit to a mono-exponential function using Scipy (Python). The data presented here are from at least two separate HPLC fractions, measured on different days.</p></sec><sec id="sec3.4"><title>Analytical ultracentrifugation</title><p id="p0100">Lispro variants (140&#8211;206&#160;&#956;M in 100&#160;mM phosphate buffer, pH 8.0) were analyzed by velocity sedimentation at the Canadian Center for Hydrodynamics at the University of Lethbridge using absorbance optics. All samples were measured at 60,000 RPM and 20 &#176;C. Data were analyzed with UltraScan III version 4.0 release 6606 (<xref rid="bib38" ref-type="bibr">38</xref>). Velocity data were initially fitted with the two-dimensional spectrum analysis (<xref rid="bib39" ref-type="bibr">39</xref>) to determine meniscus position and time- and radially-invariant noise, and to generate molecular weight distributions. Two-dimensional spectrum analysis results were refined using the genetic algorithm approach (<xref rid="bib40" ref-type="bibr">40</xref>). Sedimentation and diffusion coefficients derived from the genetic algorithm analysis were transformed to molar mass distributions, assuming a partial specific volume of 0.7248&#160;ml/g for all lispro variants. The enhanced van Holde-Weischet analysis (<xref rid="bib41" ref-type="bibr">41</xref>) was used to determine diffusion-corrected sedimentation coefficient distributions. For the K<sub>d</sub> analysis, AUC data were fitted with a discrete model genetic algorithm approach (<xref rid="bib29" ref-type="bibr">29</xref>), assuming the known molar mass of the monomer and floating the K<sub>d</sub>, k<sub>off</sub>, total concentration, partial specific volumes, and frictional ratios as reported in <xref rid="appsec1" ref-type="sec">Table&#160;S3</xref>.</p></sec><sec id="sec3.5"><title>Fibrillation lag time</title><p id="p0105">Lispro samples (60&#160;&#956;M in 100&#160;mM sodium phosphate buffer, pH 8.0) were centrifuged (22,000<italic toggle="yes">g</italic>, 1&#160;h, 4 &#176;C); 1&#160;&#956;M thioflavin T was then added. Each lispro variant was shaken continuously in a 96-well, black, clear bottom plate at 37 &#176;C, and fluorescence (444&#160;nm excitation, 485&#160;nm emission) was monitored over time. Fibrillation runs were performed on two separate HPLC fractions, each in triplicate or quadruplicate, on two separate days. The growth phase of each replicate was fit to a linear function; lag times were reported as the x-intercept.</p></sec><sec id="sec3.6"><title>ANS fluorescence</title><p id="p0110">Lispro variants (1&#160;&#956;M) were mixed with 5&#160;&#956;M ANS in 100&#160;mM phosphate buffer, pH 8.0. Fluorescence emission spectra were measured at ambient temperature (350&#160;nm excitation). Measurements for each lispro were performed in triplicate from three separate HPLC fractions.</p></sec></sec><sec sec-type="data-availability" id="sec4"><title>Data availability</title><p id="p0115">The UltraScan software used to analyze the AUC data is open source and freely available from the Github repository (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/ehb54/ultrascan3" id="intref0015">https://github.com/ehb54/ultrascan3</ext-link>). The AUC data is available in openAUC format upon request from Borries Demeler (<email>demeler@gmail.com</email>), and is stored in the UltraScan LIMS server at the Canadian Center for Hydrodynamics.</p></sec><sec sec-type="supplementary-material" id="sec5"><title>Supporting information</title><p id="p0120">This article contains <xref rid="appsec1" ref-type="sec">supporting information</xref> (<xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref>, <xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib29" ref-type="bibr">29</xref>, <xref rid="bib38" ref-type="bibr">38</xref>, <xref rid="bib39" ref-type="bibr">39</xref>, <xref rid="bib40" ref-type="bibr">40</xref>, <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>).</p></sec><sec sec-type="COI-statement"><title>Conflict of interest</title><p id="p0125">David Tirrell is an inventor on U.S. patents that describe the use of non-canonical amino acids in the engineering of insulin and other proteins. The other authors declare that they have no conflicts of interest with the contents of this article.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Haeusler</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>McGraw</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Accili</surname><given-names>D.</given-names></name></person-group><article-title>Biochemical and cellular properties of insulin receptor signalling</article-title><source>Nat. Rev. Mol. Cell Biol.</source><volume>19</volume><year>2018</year><fpage>31</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">28974775</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrm.2017.89</pub-id><pub-id pub-id-type="pmcid">PMC5894887</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Goeddel</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Kleid</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Bolivar</surname><given-names>F.</given-names></name><name name-style="western"><surname>Heyneker</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Yansura</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Crea</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Expression in Escherichia coli of chemically synthesized genes for human insulin</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>76</volume><year>1979</year><fpage>106</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">85300</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.76.1.106</pub-id><pub-id pub-id-type="pmcid">PMC382885</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Derewenda</surname><given-names>U.</given-names></name><name name-style="western"><surname>Derewenda</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Dodson</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Sparks</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Phenol stabilizes more helix in a new symmetrical zinc insulin hexamer</article-title><source>Nature</source><volume>338</volume><year>1989</year><fpage>594</fpage><lpage>596</lpage><pub-id pub-id-type="pmid">2648161</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/338594a0</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Holleman</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hoekstra</surname><given-names>J.B.L.</given-names></name></person-group><article-title>Insulin lispro</article-title><source>N.&#160;Engl. J. Med.</source><volume>337</volume><year>1997</year><fpage>176</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">9219705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM199707173370307</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Birnbaum</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Kilcomons</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>DeFelippis</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Beals</surname><given-names>J.M.</given-names></name></person-group><article-title>Assembly and dissociation of human insulin and LysB28-ProB29-insulin hexamers: a comparison study</article-title><source>Pharm. Res.</source><volume>14</volume><year>1997</year><fpage>25</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">9034217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/a:1012095115151</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Bakaysa</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Radziuk</surname><given-names>J.</given-names></name><name name-style="western"><surname>Havel</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Brader</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dodd</surname><given-names>S.W.</given-names></name><etal/></person-group><article-title>Physicochemical basis for the rapid time-action of LysB28ProB29-insulin: dissociation of a protein-ligand complex</article-title><source>Protein Sci.</source><volume>5</volume><year>1996</year><fpage>2521</fpage><lpage>2531</lpage><pub-id pub-id-type="pmid">8976561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pro.5560051215</pub-id><pub-id pub-id-type="pmcid">PMC2143322</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Brems</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Alter</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Beckage</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Chance</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Dimarchi</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Green</surname><given-names>L.K.</given-names></name><etal/></person-group><article-title>Altering the association properties of insulin by amino acid replacement</article-title><source>Protein Eng.</source><volume>5</volume><year>1992</year><fpage>527</fpage><lpage>533</lpage><pub-id pub-id-type="pmid">1438163</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/protein/5.6.527</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Brange</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ribel</surname><given-names>U.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Dodson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hanse</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Havelund</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Monomeric insulins obtained by protein engineering and their medical implications</article-title><source>Nature</source><volume>333</volume><year>1988</year><fpage>679</fpage><lpage>682</lpage><pub-id pub-id-type="pmid">3287182</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/333679a0</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Rakatzi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ramrath</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ledwig</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dransfeld</surname><given-names>O.</given-names></name><name name-style="western"><surname>Bartels</surname><given-names>T.</given-names></name><name name-style="western"><surname>Seipke</surname><given-names>G.</given-names></name><etal/></person-group><article-title>A&#160;novel insulin analog with unique properties: LysB3 ,GluB29 insulin induces prominent activation of insulin receptor substrate 2, but marginal phosphorylation of insulin receptor substrate 1</article-title><source>Diabetes</source><volume>52</volume><year>2003</year><fpage>2227</fpage><lpage>2238</lpage><pub-id pub-id-type="pmid">12941761</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/diabetes.52.9.2227</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Mathieu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gillard</surname><given-names>P.</given-names></name><name name-style="western"><surname>Benhalima</surname><given-names>K.</given-names></name></person-group><article-title>Insulin analogues in type 1 diabetes mellitus: getting better all the time</article-title><source>Nat. Rev. Endocrinol.</source><volume>13</volume><year>2017</year><fpage>385</fpage><lpage>399</lpage><pub-id pub-id-type="pmid">28429780</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrendo.2017.39</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Akbarian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yousefi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Farjadian</surname><given-names>F.</given-names></name><name name-style="western"><surname>Uversky</surname><given-names>V.N.</given-names></name></person-group><article-title>Insulin fibrillation: toward strategies for attenuating the process</article-title><source>Chem. Commun.</source><volume>56</volume><year>2020</year><fpage>11354</fpage><lpage>11373</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d0cc05171c</pub-id><pub-id pub-id-type="pmid">32990302</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Brems</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Bryant</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chance</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Green</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Long</surname><given-names>H.B.</given-names></name><etal/></person-group><article-title>Improved insulin stability through amino acid substitution</article-title><source>Protein Eng.</source><volume>5</volume><year>1992</year><fpage>519</fpage><lpage>525</lpage><pub-id pub-id-type="pmid">1438162</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/protein/5.6.519</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Lepore</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pampanelli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fanelli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Porcellati</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bartocci</surname><given-names>L.</given-names></name><name name-style="western"><surname>Di Vincenzo</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro</article-title><source>Diabetes</source><volume>49</volume><year>2000</year><fpage>2142</fpage><lpage>2148</lpage><pub-id pub-id-type="pmid">11118018</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/diabetes.49.12.2142</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Ganguly</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Basu</surname><given-names>G.</given-names></name></person-group><article-title>Conformational landscape of substituted prolines</article-title><source>Biophys. Rev.</source><volume>12</volume><year>2020</year><fpage>25</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">31953795</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12551-020-00621-8</pub-id><pub-id pub-id-type="pmcid">PMC7040156</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Chin</surname><given-names>J.W.</given-names></name></person-group><article-title>Expanding and reprogramming the genetic code</article-title><source>Nature</source><volume>550</volume><year>2017</year><fpage>53</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">28980641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature24031</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Renner</surname><given-names>C.</given-names></name><name name-style="western"><surname>Alefelder</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bae</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Budisa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Huber</surname><given-names>R.</given-names></name><name name-style="western"><surname>Moroder</surname><given-names>L.</given-names></name></person-group><article-title>Fluoroprolines as tools for protein design and engineering</article-title><source>Angew. Chem. Int. Ed. Engl.</source><volume>40</volume><year>2001</year><fpage>923</fpage><lpage>925</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1521-3773(20010302)40:5&lt;923::AID-ANIE923&gt;3.0.CO;2-#</pub-id><pub-id pub-id-type="pmid">29712173</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Holmgren</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Bretscher</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Raines</surname><given-names>R.T.</given-names></name></person-group><article-title>Code for collagen&#8217;s stability deciphered</article-title><source>Nature</source><volume>392</volume><year>1998</year><fpage>666</fpage><lpage>667</lpage><pub-id pub-id-type="pmid">9565027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/33573</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Lummis</surname><given-names>S.C.R.</given-names></name><name name-style="western"><surname>Beene</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>L.W.</given-names></name><name name-style="western"><surname>Lester</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Broadhurst</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Dougherty</surname><given-names>D.A.</given-names></name></person-group><article-title>Cis&#8211;trans isomerization at a proline opens the pore of a neurotransmitter-gated ion channel</article-title><source>Nature</source><volume>438</volume><year>2005</year><fpage>248</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">16281040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature04130</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Torbeev</surname><given-names>V.Y.</given-names></name><name name-style="western"><surname>Hilvert</surname><given-names>D.</given-names></name></person-group><article-title>Both the cis-trans equilibrium and isomerization dynamics of a single proline amide modulate &#946;2-microglobulin amyloid assembly</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>110</volume><year>2013</year><fpage>20051</fpage><lpage>20056</lpage><pub-id pub-id-type="pmid">24262149</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1310414110</pub-id><pub-id pub-id-type="pmcid">PMC3864314</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Naduthambi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zondlo</surname><given-names>N.J.</given-names></name></person-group><article-title>Stereoelectronic tuning of the structure and stability of the trp cage miniprotein</article-title><source>J.&#160;Am. Chem. Soc.</source><volume>128</volume><year>2006</year><fpage>12430</fpage><lpage>12431</lpage><pub-id pub-id-type="pmid">16984189</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ja0648458</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Crespo</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Rubini</surname><given-names>M.</given-names></name></person-group><article-title>Rational design of protein stability: effect of (2S,4R)-4-Fluoroproline on the stability and folding pathway of ubiquitin</article-title><source>PLoS One</source><volume>6</volume><year>2011</year><object-id pub-id-type="publisher-id">e19425</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0019425</pub-id><pub-id pub-id-type="pmcid">PMC3095602</pub-id><pub-id pub-id-type="pmid">21625626</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Rubini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sch&#228;rer</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Capitani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Glockshuber</surname><given-names>R.</given-names></name></person-group><article-title>(4R)- and (4S)-fluoroproline in the conserved cis-prolyl peptide bond of the thioredoxin fold: tertiary structure context dictates ring puckering</article-title><source>Chembiochem.</source><volume>14</volume><year>2013</year><fpage>1053</fpage><lpage>1057</lpage><pub-id pub-id-type="pmid">23712956</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cbic.201300178</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Lieblich</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Tirrell</surname><given-names>D.A.</given-names></name></person-group><article-title>Replacement of ProB28 by pipecolic acid protects insulin against fibrillation and slows hexamer dissociation</article-title><source>J.&#160;Polym. Sci. A Polym. Chem.</source><volume>57</volume><year>2019</year><fpage>264</fpage><lpage>267</lpage></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Lieblich</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Cahn</surname><given-names>J.K.B.</given-names></name><name name-style="western"><surname>Rawson</surname><given-names>J.</given-names></name><name name-style="western"><surname>LeBon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Teresa Ku</surname><given-names>H.</given-names></name><etal/></person-group><article-title>4S-Hydroxylation of insulin at ProB28 accelerates hexamer dissociation and delays fibrillation</article-title><source>J.&#160;Am. Chem. Soc.</source><volume>139</volume><year>2017</year><fpage>8384</fpage><lpage>8387</lpage><pub-id pub-id-type="pmid">28598606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jacs.7b00794</pub-id><pub-id pub-id-type="pmcid">PMC5812673</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Breunig</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Quijano</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Donohue</surname><given-names>C.</given-names></name><name name-style="western"><surname>Henrickson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Demeler</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ku</surname><given-names>H.T.</given-names></name><etal/></person-group><article-title>Incorporation of aliphatic proline residues into recombinantly-produced insulin</article-title><source>ACS Chem. Biol.</source><volume>18</volume><year>2023</year><fpage>2574</fpage><lpage>2581</lpage><pub-id pub-id-type="pmid">37960878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acschembio.3c00561</pub-id><pub-id pub-id-type="pmcid">PMC10728891</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Breunig</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Tirrell</surname><given-names>D.A.</given-names></name></person-group><article-title>Incorporation of proline analogs into recombinant proteins expressed in Escherichia coli</article-title><source>Methods Enzymol.</source><volume>656</volume><year>2021</year><fpage>545</fpage><lpage>571</lpage><pub-id pub-id-type="pmid">34325798</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.mie.2021.05.008</pub-id><pub-id pub-id-type="pmcid">PMC9009304</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Plum</surname><given-names>A.</given-names></name><name name-style="western"><surname>Agers&#248;</surname><given-names>H.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>L.</given-names></name></person-group><article-title>Pharmacokinetics of the rapid-acting insulin analog, insulin aspart, in rats, dogs, pigs, and pharcamodynamics of insulin aspart in pigs</article-title><source>Drug Metab. Dispos.</source><volume>28</volume><year>2000</year><fpage>155</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">10640512</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Menting</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Whittaker</surname><given-names>J.</given-names></name><name name-style="western"><surname>Margets</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Whittaker</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>G.K.-W.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>B.J.</given-names></name><etal/></person-group><article-title>How insulin engages its primary binding site on the insulin receptor</article-title><source>Nature</source><volume>493</volume><year>2013</year><fpage>241</fpage><lpage>245</lpage><pub-id pub-id-type="pmid">23302862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature11781</pub-id><pub-id pub-id-type="pmcid">PMC3793637</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Demeler</surname><given-names>B.</given-names></name><name name-style="western"><surname>Brookes</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schirf</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C.A.</given-names></name></person-group><article-title>Characterization of reversible associations by sedimentation velocity with UltraScan</article-title><source>Macromol. Biosci.</source><volume>10</volume><year>2010</year><fpage>775</fpage><lpage>782</lpage><pub-id pub-id-type="pmid">20486142</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mabi.200900481</pub-id><pub-id pub-id-type="pmcid">PMC12146795</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Rahuel-Clermont</surname><given-names>S.</given-names></name><name name-style="western"><surname>French</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Kaarsholm</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>M.F.</given-names></name></person-group><article-title>Mechanisms of stabilization of the insulin hexamer through allosteric ligand interactions</article-title><source>Biochemistry</source><volume>36</volume><year>1997</year><fpage>5837</fpage><lpage>5845</lpage><pub-id pub-id-type="pmid">9153424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/bi963038q</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Semisotnov</surname><given-names>G.V.</given-names></name><name name-style="western"><surname>Rodionova</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Razgulyaev</surname><given-names>O.I.</given-names></name><name name-style="western"><surname>Uversky</surname><given-names>V.N.</given-names></name><name name-style="western"><surname>Gripas</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Gilmanshin</surname><given-names>R.I.</given-names></name></person-group><article-title>Study of the &#8220;molten globule&#8221; intermediate state in protein folding by a hydrophobic fluorescent probe</article-title><source>Biopolymers</source><volume>31</volume><year>1991</year><fpage>119</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">2025683</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bip.360310111</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Shoulders</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Raines</surname><given-names>R.T.</given-names></name></person-group><article-title>Collagen structure and stability</article-title><source>Annu. Rev. Biochem.</source><volume>78</volume><year>2009</year><fpage>929</fpage><lpage>958</lpage><pub-id pub-id-type="pmid">19344236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.biochem.77.032207.120833</pub-id><pub-id pub-id-type="pmcid">PMC2846778</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Brange</surname><given-names>J.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Laursen</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Meyn</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rasmussen</surname><given-names>E.</given-names></name></person-group><article-title>Toward understanding insulin fibrillation</article-title><source>J.&#160;Pharm. Sci.</source><volume>86</volume><year>1997</year><fpage>517</fpage><lpage>525</lpage><pub-id pub-id-type="pmid">9145374</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/js960297s</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Pandyarajan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>N.B.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Whittaker</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ismail-Beigi</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Biophysical optimization of a therapeutic protein by nonstandard mutagenesis: studies of an iodo-insulin derivative</article-title><source>J.&#160;Biol. Chem.</source><volume>289</volume><year>2014</year><fpage>23367</fpage><lpage>23381</lpage><pub-id pub-id-type="pmid">24993826</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M114.588277</pub-id><pub-id pub-id-type="pmcid">PMC4156050</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Torbeev</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ebert</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Dolenc</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hilvert</surname><given-names>D.</given-names></name></person-group><article-title>Substitution of proline32 by &#945;-methylproline preorganizes &#946;2-microglobulin for oligomerization but not for aggregation into amyloids</article-title><source>J.&#160;Am. Chem. Soc.</source><volume>137</volume><year>2015</year><fpage>2524</fpage><lpage>2535</lpage><pub-id pub-id-type="pmid">25633201</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ja510109p</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Reichel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rietzsch</surname><given-names>H.</given-names></name><name name-style="western"><surname>K&#246;hler</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pf&#252;tzner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gudat</surname><given-names>U.</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>J.</given-names></name></person-group><article-title>Cessation of insulin infusion at night-time during CSII-therapy: comparison of regular human insulin and insulin lispro</article-title><source>Exp. Clin. Endocrinol. Diabetes</source><volume>106</volume><year>1998</year><fpage>168</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">9710355</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0029-1211971</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Weiss</surname><given-names>M.A.</given-names></name></person-group><article-title>Design of ultra-stable insulin analogues for the developing world</article-title><source>J.&#160;Health Specialties</source><volume>1</volume><year>2013</year><fpage>59</fpage><lpage>70</lpage></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Demeler</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gorbet</surname><given-names>G.E.</given-names></name></person-group><article-title>Analytical ultracentrifugation data analysis with ultrascan-III</article-title><source>Anal. Ultracentrifugation</source><year>2016</year><pub-id pub-id-type="doi">10.1007/978-4-431-55985-6_8</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Brookes</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Demeler</surname><given-names>B.</given-names></name></person-group><article-title>A&#160;two-dimensional spectrum analysis for sedimentation velocity experiments of mixtures with heterogeneity in molecular weight and shape</article-title><source>Eur. Biophys. J.</source><volume>39</volume><year>2010</year><fpage>405</fpage><lpage>414</lpage><pub-id pub-id-type="pmid">19247646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00249-009-0413-5</pub-id><pub-id pub-id-type="pmcid">PMC12146834</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="book" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Brookes</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Demeler</surname><given-names>B.</given-names></name></person-group><part-title>Parsimonious regularization using genetic algorithms applied to the analysis of analytical ultracentrifugation experiments</part-title><source>Proceedings of GECCO 2007: Genetic and Evolutionary Computation Conference</source><year>2007</year><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Demeler</surname><given-names>B.</given-names></name><name name-style="western"><surname>Van Holde</surname><given-names>K.E.</given-names></name></person-group><article-title>Sedimentation velocity analysis of highly heterogeneous systems</article-title><source>Anal. Biochem.</source><volume>335</volume><year>2004</year><fpage>279</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">15556567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ab.2004.08.039</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Min</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Son</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.W.</given-names></name></person-group><article-title>Increased expression, folding and enzyme reaction rate of recombinant human insulin by selecting appropriate leader peptide</article-title><source>J.&#160;Biotechnol.</source><volume>151</volume><year>2011</year><fpage>350</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">21219941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbiotec.2010.12.023</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>W.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Andrew Jones</surname><given-names>J.</given-names></name><name name-style="western"><surname>Linhardt</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Koffas</surname><given-names>M.</given-names></name></person-group><article-title>Production of chondroitin in metabolically engineered E. coli</article-title><source>Metab. Eng.</source><volume>27</volume><year>2015</year><fpage>92</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">25461828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymben.2014.11.003</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><title>Supporting information</title><p id="p0145">
<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Supporting information</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.pdf" position="float" orientation="portrait"/></supplementary-material>
</p></sec><ack id="ack0010"><title>Acknowledgments</title><p id="p0130">We sincerely thank Chad D. Paavola, Michael P. Akers, Julie S. Moyers, and Alborz Mahdavi for advice on proinsulin refolding, Sophie E. Miller for help with sample preparation for mouse experiments, and Scott Virgil for expertise in chromatography. Circular dichroism spectroscopy was performed at the Beckman Institute Laser Resource Center at Caltech with assistance from Jay Winkler. Electron microscopy was performed at the Beckman Institute Resource Center for Transmission Electron Microscopy at Caltech with input from Songye Chen. Mass spectrometry was performed at the Caltech Multiuser Mass Spectrometry Laboratory in the Division of Chemistry and Chemical Engineering with the help of Mona Shahgholi.</p><sec id="sec6"><title>Author contributions</title><p id="p0135">S. L. B., A. M. C., and D. A. T. conceptualization; S. L. B., A. M. C., J. L., J. C. Q., M. R., and J. R. investigation; S. L. B. writing&#8211;original draft; B. D., H. T. K., and D. A. T. supervision; D. A. T. writing&#8211;review and editing.</p></sec><sec id="sec7"><title>Funding and additional information</title><p id="p0140">This work was supported by grants from the <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source> (1R01GM134013-01, D. A. T.; 1R01GM120600, B. D.), the <funding-source id="gs9"><institution-wrap><institution-id institution-id-type="doi">10.13039/100008871</institution-id><institution>Juvenile Diabetes Research Foundation</institution></institution-wrap></funding-source> (3-IND-2015-118-I-X, D. A. T.), the <funding-source id="gs10">Canada 150 Research Chairs program</funding-source> (C150-2017-00015, B. D.), the <funding-source id="gs4">Canada Foundation for Innovation</funding-source> (CFI-37589, B. D.), and the <funding-source id="gs6">Canadian Natural Science and Engineering Research Council</funding-source> (DG-RGPIN-2019-05637, B. D.). UltraScan supercomputer calculations were supported through <funding-source id="gs11"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000001</institution-id><institution>NSF</institution></institution-wrap></funding-source>/XSEDE grant TG-MCB070039N (B. D.) and <funding-source id="gs12"><institution-wrap><institution-id institution-id-type="doi">10.13039/100005518</institution-id><institution>University of Texas</institution></institution-wrap></funding-source> grant TG457201 (B. D.). S. L. B. was supported by a <funding-source id="gs8"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source> Graduate Research Fellowship under grant number 1745301. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</p></sec></ack></back></article></pmc-articleset>